

Learner Notification

Primer on Tumor Immunology & Cancer Immunotherapy
November 7, 2019
National Harbor, MD

Acknowledgement of Financial Commercial Support

Bristol-Myers Squibb, Celgene Corporation, Genentech, Merck & Co. Inc., Pfizer Inc.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. If you need MOC credit, you also need to pass a posttest with a score of at least 80%. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians / Nurses / Pharmacists



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society for Immunotherapy of Cancer. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™ for physicians and 6.25 contact hours for nurses and 6.25 of knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

American Board of Internal Medicine MOC Credits

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.25 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. **You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS.**

Objectives - After Attending This Program You Should Be Able To:

1. Describe the key principles of tumor immunology and immunotherapy.
2. Summarize the basic principles of passive immunotherapy, in which antibodies or T lymphocytes generated outside of the patient are administered with therapeutic intent.
3. Discuss the techniques involved in active immunotherapy, including tumor antigen vaccination as well as immune checkpoint blockade.
4. Outline immune monitoring techniques, both in peripheral blood and sera, as well as in patient samples collected in pre-surgical trials.
5. Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.

First Name	Last Name	Commercial Interest - Relationship
Julie	Brahmer	Merck: Scientific Medical Advisor; Genentech/Roche: Scientific Medical Advisor; AstraZeneca/MedImmune: Scientific Medical Advisor; Syndax: Scientific Medical Advisor; BMS: Scientific Medical Advisor; BMS: Grant Support; Eli Lilly: Scientific Medical Advisor; Amgen: Scientific Medical Advisor; Janssen: Scientific Medical Advisor; Celgene: Scientific Medical Advisor
Tyler	Curiel	Agenus: Consultant; Xencor: Consultant; Dr. Reddy: Consultant
Michael	Curran	Aduro: Ownership Interest - Spouse/Partner; Molecular Templates: Ownership Interest - Spouse/Partner; Merck: Consultant; Alligator: Consultant; Aptevo: Advisory Committee Member; Mabimmune: Advisory Committee Member; Pieris: Consultant; Nurix: Advisory Committee Member; Servier: Consultant; Inovio: Advisory Committee Member; Xencor: Advisory Committee Member; Oncoresponse: Advisory Committee Member; ImmunOS: Consultant; ImmunOS: Ownership Interest; ImmunoMet: Consultant; Agenus: Consultant; Cytomx: Ownership Interest - Spouse/Partner; ImmunoGenesis: Ownership Interest
Tanja	de Gruijl	DCPrime: Advisory Committee Member; Idera Pharmaceuticals: Research Support
Greg	Delgoffe	TTMS, Inc.: Contracted Research, Ownership Interest; Pieris Pharmaceuticals: Advisory Committee Member; Western Oncolytics: Advisory Committee Member
Charles	Drake	Compugen: Ownership Interest; Harpoon: Ownership Interest; Kleo: Ownership Interest; Potenza: Ownership Interest; Tizona: Ownership Interest; Agenus: Consultant; Dendreon: Consultant; Janssen: Consultant; Lilly: Consultant; Merck: Consultant; Medimmune: Consultant; Pierre Fabre: Consultant; Roche/Genentech: Consultant; Aduro Biotech: Research Funding; Bristol Myers Squibb: Research Funding; Janssen: Research Funding
Leisha	Emens	Genentech/Roche: Consultant; Genentech/Roche: Contracted Research; Lilly: Advisory Committee Member; Syndax: Chair, DSMB; MacroGenics: Advisory Committee Member; Replimune: Scientific Medical Advisor; Aduro Biotech: Royalties for IP; AstraZeneca: Contracted Research; Aduro Biotech: Contracted Research; Corvus: Contracted Research; EMD Serono: Contracted Research; Merck: Contracted Research
Amir	Horowitz	Genentech: Consultant; HTG Molecular: Advisory Committee Member; Zumutor Biologics: Contracted Research
Jarushka	Naidoo	Bristol-Myers Squibb: Consultant, Honoraria; Genentech/Roche: Consultant; AstraZeneca/MedImmune: Consultant, Contracted Research, Honoraria
Jonathan	Powell	Dracen: Ownership Interest

How to Get Your Certificate:

1. Go to [SITC Primer on Tumor Immunology & Cancer Immunotherapy](#)
or
1. To take the MOC Post-Test for ABIM MOC Credit, click here: [2019 SITC Primer ABIM MOC Post-Test](#)
2. Take the Post-Test/Evaluate the meeting.
3. Print all pages of your certificate for your records.

Questions? Email Certificate@AmedcoEmail.com